Start
Entdecken
nav.journalClub
Trends
Mehr
synapse
⌘+K
Sprache
Deutsch
March 3, 2026
A ROS-responsive TPZ prodrug micelle for co-delivery with doxorubicin in synergistic cancer therapy
XM
Xiaojun Ma
HM
Hongjuan Ma
YS
Yingjie Shen
See all
Key Points
Enhanced cancer therapy observed with ROS-responsive prodrug micelles co-delivering doxorubicin.
Synergistic effects noted, with improved efficacy in targeting cancer cells.
Assessment using a novel micelle formulation to deliver both TPZ and doxorubicin effectively.
Findings emphasize the potential for better treatment options in cancer, promoting further investigation.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
A ROS-responsive TPZ prodrug micelle for co-delivery with doxorubicin in synergistic cancer therapy | Synapse
Cite This Study
Copy
Ma et al. (Thu,) studied this question.
synapsesocial.com/papers/69a75b1dc6e9836116a21d97
https://doi.org/https://doi.org/10.1016/j.cclet.2026.112466